Literature DB >> 12580940

Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?

Alan D Rogol1, Sandra L Blethen, Judy P Sy, Johannes D Veldhuis.   

Abstract

OBJECTIVE: To compare the relative utility of GH secretion via pharmacological stimulation, overnight serial sampling, IGF-I levels and auxological variables as predictors of change in height standard deviation score (deltaHt SDS) during GH treatment.
DESIGN: A multicentre observational study. PATIENTS: Prepubertal children (n = 825) with idiopathic growth failure who were subsequently treated with GH were divided into two groups, based on their maximum GH response to pharmacological stimulation testing: (1) idiopathic GH deficiency (IGHD), defined by a maximum GH response < 10 microg/l (n = 300); and (2) idiopathic short stature (ISS), with a maximum GH response > or = 10 microg/l (n = 525) (GH conversion factor: 3 IU = 1 mg). MEASUREMENTS: Overnight spontaneous GH secretion was measured in all patients. The following characteristics of spontaneous GH secretion were studied: maximum or peak GH, mean peak GH, number of GH peaks, pooled GH, mean GH, and approximate entropy of GH secretion.
RESULTS: Although children with IGHD had lower indices of spontaneous GH secretion, there were no differences between IGHD and ISS groups in baseline Ht SDS, growth rate or IGF-I level. The dose and duration of GH therapy were similar. There was no statistically significant difference in the mean (+/- SD) change in Ht SDS (deltaHt SDS) in the two groups (IGHD 1.3 +/- 0.9 and ISS 1.2 +/- 0.8). Measures of spontaneous secretion, such as peak GH, mean of GH peaks, mean area under GH peaks, and mean GH, as well as IGF-I concentrations, were all statistically significantly correlated with deltaHt SDS in IGHD children (P < 0.0001). A significant correlation was also observed for pooled GH (P = 0.002) and approximate entropy (P = 0.01). Children with the most severe ISS (Ht SDS < -3.33) demonstrated a more disorganized pattern of GH secretion compared to children who were not as short (Ht SDS -2.33 to -1.64), as indicated by a higher approximate entropy (0.673 +/- 0.193 vs. 0.607 +/- 0.161, P < 0.004). This increased disorder in GH secretion was accompanied by lower IGF-I levels (104 +/- 99 microg/l vs. 137 +/- 74 microg/l, P < 0.001), even though pooled GH concentrations were indistinguishable between the two groups (2.2 +/- 1.3 microg/l vs. 2.0 +/- 1.0 microg/l). Children with IGHD demonstrated lower approximate entropy than did those with ISS (0.551 +/- 0.235 vs. 0.631 +/- 0.182, P < 0.0001). Duration of GH treatment, height deficit and genetic potential (midparental Ht SDS) were the most important variables influencing deltaHt SDS in children receiving GH therapy. Maximum stimulated GH, IGF-I and indices of spontaneous GH secretion also correlated with deltaHt SDS, but their relative importance varied among diagnostic groups.
CONCLUSIONS: Patients with GH deficiency demonstrate a reduced capacity for GH secretion, while those with idiopathic short stature exhibit a more disorderly and less functional secretory pattern. Although effective in predicting a response to GH treatment in patients with severe GH deficiency, overnight serial sampling is less practical than other methods currently available. In addition, serial sampling was less useful as a predictor of growth response to exogenous GH in patients with idiopathic short stature.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12580940     DOI: 10.1046/j.1365-2265.2003.01701.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Predicting response to growth hormone treatment.

Authors:  Leena Patel; Peter E Clayton
Journal:  Indian J Pediatr       Date:  2011-11-22       Impact factor: 1.967

Review 2.  Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure.

Authors:  Ross G Clark
Journal:  Pediatr Nephrol       Date:  2005-01-29       Impact factor: 3.714

3.  Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency.

Authors:  T J Cole; P C Hindmarsh; D B Dunger
Journal:  Arch Dis Child       Date:  2004-11       Impact factor: 3.791

4.  Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.

Authors:  Giulia Rodari; E Profka; F Giacchetti; I Cavenaghi; M Arosio; C Giavoli
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

5.  The Effect of Recombinant Growth Hormone Treatment in Children with Idiopathic Short Stature and Low Insulin-Like Growth Factor-1 Levels.

Authors:  Zeynep Şıklar; Pınar Kocaay; Emine Çamtosun; Mehmet İsakoca; Bülent Hacıhamdioğlu; Şenay Savaş Erdeve; Merih Berberoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12

6.  Development and Validation of a Prediction Rule for Growth Hormone Deficiency Without Need for Pharmacological Stimulation Tests in Children With Risk Factors.

Authors:  Florencia Clément; Romina P Grinspon; Daniel Yankelevich; Sabrina Martín Benítez; María Carolina De La Ossa Salgado; María Gabriela Ropelato; María Gabriela Ballerini; Ana C Keselman; Débora Braslavsky; Patricia Pennisi; Ignacio Bergadá; Gabriela P Finkielstain; Rodolfo A Rey
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.